deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04402073

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Medulloblastoma
Interventions Cisplatin Lomustine Sonidegib Vincristine radiotherapy
Updated 13 times since 2020 Last updated: Oct 21, 2025 Started: Nov 11, 2022 Primary completion: Jun 16, 2025 Completion: Sep 10, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor accrual

Other terminated trials from European Organisation for Research and Treatment of Cancer - EORTC

See all terminations from European Organisation for Research and Treatment of Cancer - EORTC

Other Medulloblastoma trials with similar outcome

Browse all Medulloblastoma trials

Listed as NCT04402073, this PHASE2 trial focuses on Medulloblastoma and remains terminated or withdrawn. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 13 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Jan 2024 · 4 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

13 versions recorded

  1. Nov 2025 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 8 earlier versions

  1. Sep 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  2. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  4. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Nov 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE2

  6. Jun 2022 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE2

  7. Jan 2021 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE2

  8. Jun 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Organisation for Research and Treatment of Cancer - EORTC
Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Badalona, Spain , Barcelona, Spain , Bochum, Germany , Bologna, Italy , Bonn, Germany , Brisbane, Australia , Dresden, Germany , Erfurt, Germany , Essen, Germany and 34 more locations